KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBITDA (2016 - 2025)

Historic EBITDA for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$7.7 million.

  • Arbutus Biopharma's EBITDA rose 6059.29% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 4425.21%. This contributed to the annual value of -$69.6 million for FY2024, which is 162.19% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's EBITDA is -$7.7 million, which was up 6059.29% from $2.5 million recorded in Q2 2025.
  • Arbutus Biopharma's EBITDA's 5-year high stood at $2.5 million during Q2 2025, with a 5-year trough of -$24.6 million in Q1 2025.
  • In the last 5 years, Arbutus Biopharma's EBITDA had a median value of -$18.5 million in 2022 and averaged -$16.7 million.
  • As far as peak fluctuations go, Arbutus Biopharma's EBITDA plummeted by 3904.76% in 2021, and later soared by 11267.93% in 2025.
  • Over the past 5 years, Arbutus Biopharma's EBITDA (Quarter) stood at -$21.5 million in 2021, then grew by 0.25% to -$21.4 million in 2022, then rose by 11.99% to -$18.8 million in 2023, then surged by 33.27% to -$12.6 million in 2024, then soared by 38.9% to -$7.7 million in 2025.
  • Its EBITDA was -$7.7 million in Q3 2025, compared to $2.5 million in Q2 2025 and -$24.6 million in Q1 2025.